Which statement correctly lists the minimum criteria for regulatory reporting of ADRs?

Which statement correctly lists the minimum criteria for regulatory reporting of ADRs?

• A. Only identifiable patient is required.
• B. Identifiable reporting source and event must be met.
• C. Only suspect medicinal product is required.
• D. All four minimum criteria are met: identifiable patient, suspect medicinal product, identifiable reporting source, and a serious and unexpected event with a reasonable suspected causal relationship.

Answer: (D)

The key idea is that regulatory ADR reports must be complete enough to allow authorities to take action and assess risk. For a report to meet the minimum criteria, four elements must be present. First, the patient must be identifiable. This allows follow-up to obtain additional information if needed and ensures the report can be linked to the correct individual. Second, there must be a suspect medicinal product. Identifying which drug is implicated is essential for attributing risk and guiding safety signals to the correct product. Third, the reporting source must be identifiable. Knowing who reported the event—whether a clinician, the patient, or a company—establishes credibility and provides a reliable point of contact for further information. Fourth, the adverse event itself must be serious and unexpected and have a reasonable suspected causal relationship to the medicinal product. Seriousity prompts regulatory concern and potential action; being unexpected means the event isn’t already described in labeling, and a plausible causal link supports prioritizing investigation. If any of these four elements are missing, the report would not meet the standard for regulatory reporting.

The key idea is that regulatory ADR reports must be complete enough to allow authorities to take action and assess risk. For a report to meet the minimum criteria, four elements must be present.

First, the patient must be identifiable. This allows follow-up to obtain additional information if needed and ensures the report can be linked to the correct individual.

Second, there must be a suspect medicinal product. Identifying which drug is implicated is essential for attributing risk and guiding safety signals to the correct product.

Third, the reporting source must be identifiable. Knowing who reported the event—whether a clinician, the patient, or a company—establishes credibility and provides a reliable point of contact for further information.

Fourth, the adverse event itself must be serious and unexpected and have a reasonable suspected causal relationship to the medicinal product. Seriousity prompts regulatory concern and potential action; being unexpected means the event isn’t already described in labeling, and a plausible causal link supports prioritizing investigation.

If any of these four elements are missing, the report would not meet the standard for regulatory reporting.